Factor V plays a pivotal role in hemostasis, and in the pathology of venous thrombosis. Fluorescence-based equilibrium binding, steady-state and rapid reaction kinetics are proposed to define the molecular mechanisms of the procoagulant activation of human factor V, factor Va cofactor activity in regulating prothrombin (ProT) activation, and the mechanism of the anticoagulant inactivation of factor Va by activated protein C (ARC). The broad goal is an understanding of the interdependence of these mechanisms in hemostasis and thrombotic disease.
Aim 1 will test the hypothesis that factor V activation by thrombin and meizothrombin (MzT) involves exosite I and ll-mediated substrate recognition of factor V and its activation intermediates that order the pathway and control the generation of specific binding sites for factor Xa and ProT.
Aim 2 will evaluate the hypothesis that factor Va cofactor activity involves a two-step mechanism of substrate recognition of ProT and its activation intermediates, with initial formation of a complex in which the factor Xa catalytic site is accessible, followed by conformational engagement of the catalytic site. (Pro)exosite I on ProT substrate species is postulated to control one or both steps in substrate recognition through interactions with factor Va in the prothrombinase complex.
Aim 3 will elucidate the mechanism of ordered cleavage of the ProT activation pathway hypothesized to result from ProT binding in two alternate conformations that present the Arg320 and Arg271 cleavage sites sequentially to factor Xa. Differential (pro)exosite I expression accompanying ProT activation is postulated to switch ProT between these conformations, thereby controlling the pathway.
Aim 4 will test the hypothesis that regulation of the rate and pathway of factor Va inactivation by APC through ordered cleavages at Arg506, Arg306, and Arg679 is achieved by exosite-mediated competitive binding of factor Xa and APC to factor Va for cleavage at Arg506, and specific acceleration of cleavage at Arg306 by protein S. APC-factor Va substrate recognition is postulated to follow the two-step mechanism in which factor Xa and protein S switch APC between alternate bound conformations to direct cleavage at Arg506 and Arg306. New knowledge of exosite interactions in the physiological substrate specificity of coagulation proteinases will facilitate the development of novel exosite-directed anticoagulants. Relevance. Blood clots occurring abnormally in the deep veins of the legs can break apart in the circulation and lodge in the lungs, resulting in life-threatening thrombosis. Individuals with fairly common genetic defects in the coagulation factors, factor V, protein C, protein S, and prothrombin, and women taking oral contraceptives have a higher risk of clotting in veins. The goal of the research is to understand how these proteins work in normal clotting and in clotting diseases. The results may lead to new drugs for treatment of clotting diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL038779-23
Application #
7788848
Study Section
Special Emphasis Panel (ZRG1-HEME-D (02))
Program Officer
Link, Rebecca P
Project Start
1994-04-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2012-03-31
Support Year
23
Fiscal Year
2010
Total Cost
$307,000
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pathology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Tormoen, Garth W; Cianchetti, Flor A; Bock, Paul E et al. (2012) Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Front Oncol 2:110
Kroh, Heather K; Panizzi, Peter; Tchaikovski, Svetlana et al. (2011) Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo. J Biol Chem 286:23345-56
Berny-Lang, M A; Aslan, J E; Tormoen, G W et al. (2011) Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol 8:015014
Newell-Caito, Jennifer L; Laha, Malabika; Tharp, Anthony C et al. (2011) Notecarin D binds human factor V and factor Va with high affinity in the absence of membranes. J Biol Chem 286:38286-97
Tormoen, G W; Rugonyi, S; Gruber, A et al. (2011) The role of carrier number on the procoagulant activity of tissue factor in blood and plasma. Phys Biol 8:066005
Panizzi, Peter; Nahrendorf, Matthias; Figueiredo, Jose-Luiz et al. (2011) In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med 17:1142-6
Corral-Rodriguez, Maria Angeles; Bock, Paul E; Hernandez-Carvajal, Erick et al. (2011) Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction. Blood 117:7164-73
Nicolaes, Gerry A F; Bock, Paul E; Segers, Kenneth et al. (2010) Inhibition of thrombin formation by active site mutated (S360A) activated protein C. J Biol Chem 285:22890-900
Berny, Michelle A; Munnix, Imke C A; Auger, Jocelyn M et al. (2010) Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One 5:e10415
Smith, Stephen B; Verhamme, Ingrid M; Sun, Mao-fu et al. (2008) Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation. J Biol Chem 283:6696-705

Showing the most recent 10 out of 19 publications